Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Economic Development Bioscience topic
No spam. Unsubscribe anytime.
Senate approves $25M bioscience investment program with oversight requirements
Summary
The Senate passed a substitute for Senate Bill 119 to create a bioscience investment mechanism that would seed up to $25 million to attract private co-investors; proponents said strict milestones and oversight limit taxpayer risk.
The New Mexico Senate on third reading approved the Finance Committee substitute for Senate Bill 119, a measure to seed the state’s Bioscience Authority with public funds to co-invest alongside private partners in early-stage bioscience companies.
Senator Hickey, sponsor of the measure, described the proposal on the floor: “Essentially, what the bill does is provide 25,000,000, puts it into the treasury until a suitable company is brought to the Bioscience Authority, and that company invests twice as much as what the state invests,” she said, adding that the authority will release funds in tranches tied to milestones.
The bill seeks to have the authority deploy state investment up to one-third of any combined authority/co‑investor investment in a company within a 12‑month period, meaning a private lead investor would provide the larger share. The substitute includes a strengthened definition of co‑investor and expanded conflict‑of‑interest provisions after discussion on the floor and in committee.
Senators debated the measure at length on policy and fiscal grounds. Senator Cervantes pressed for stronger clawback, oversight and clarity on workforce and residency requirements; Senator Hickey and floor witnesses said the authority’s structure and quarterly/annual tranches would manage risk. Supporters said the bill aims to build an in‑state bioscience ecosystem and keep talent and companies in New Mexico, while critics warned about potential weak oversight and the historical difficulty of enforcing clawbacks in bankruptcy.
A roll-call vote on the substituted measure recorded 26 senators in favor and 15 opposed; the substitute passed the Senate and will move forward for further processing.
Supporters highlighted projected job creation and wage levels in bioscience: the bill sets minimums for companies receiving state support (including minimum job counts and salary thresholds) and includes a five‑year local‑presence requirement for recipient businesses. The measure also adds public‑meeting and reporting requirements for the authority.
Provisions adopted in committee and on the floor clarified the definition of co‑investor organizations, strengthened anti‑conflict language and added tranche‑based milestone release to mitigate the state’s exposure if a company fails to meet agreed goals.
